BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 16342089)

  • 1. Comparison of the COX-inhibiting nitric oxide donator AZD3582 and rofecoxib in treating the signs and symptoms of Osteoarthritis of the knee.
    Schnitzer TJ; Kivitz AJ; Lipetz RS; Sanders N; Hee A
    Arthritis Rheum; 2005 Dec; 53(6):827-37. PubMed ID: 16342089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analgesic efficacy of the cyclooxygenase-inhibiting nitric oxide donor AZD3582 in postoperative dental pain: Comparison with naproxen and rofecoxib in two randomized, double-blind, placebo-controlled studies.
    Michael Hill C; Sindet-Pederson S; Seymour RA; Hawkesford JE; Coulthard P; Lamey PJ; Gerry Cowan C; Wickens M; Jeppsson L; Dean AD; Svensson O
    Clin Ther; 2006 Sep; 28(9):1279-95. PubMed ID: 17062301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis.
    Lohmander LS; McKeith D; Svensson O; Malmenäs M; Bolin L; Kalla A; Genti G; Szechinski J; Ramos-Remus C;
    Ann Rheum Dis; 2005 Mar; 64(3):449-56. PubMed ID: 15345500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing the efficacy of cyclooxygenase 2-specific inhibitors in treating osteoarthritis: appropriate trial design considerations and results of a randomized, placebo-controlled trial.
    Gibofsky A; Williams GW; McKenna F; Fort JG
    Arthritis Rheum; 2003 Nov; 48(11):3102-11. PubMed ID: 14613272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, safety, and tolerability of the cyclooxygenase-inhibiting nitric oxide donator naproxcinod in treating osteoarthritis of the hip or knee.
    Karlsson J; Pivodic A; Aguirre D; Schnitzer TJ
    J Rheumatol; 2009 Jun; 36(6):1290-7. PubMed ID: 19411388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of rofecoxib, celecoxib, and acetaminophen in patients with osteoarthritis of the knee. A combined analysis of the VACT studies.
    Schnitzer TJ; Weaver AL; Polis AB; Petruschke RA; Geba GP;
    J Rheumatol; 2005 Jun; 32(6):1093-105. PubMed ID: 15940774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal effects of the cyclooxygenase-inhibiting nitric oxide donator AZD3582 compared with rofecoxib and naproxen during normal and low sodium intake.
    Huledal G; Jonzon B; Malmenäs M; Hedman A; Andersson LI; Odlind B; Brater DC
    Clin Pharmacol Ther; 2005 May; 77(5):437-50. PubMed ID: 15900289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
    Sowers JR; White WB; Pitt B; Whelton A; Simon LS; Winer N; Kivitz A; van Ingen H; Brabant T; Fort JG;
    Arch Intern Med; 2005 Jan; 165(2):161-8. PubMed ID: 15668361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. Rofecoxib Osteoarthritis Pilot Study Group.
    Ehrich EW; Schnitzer TJ; McIlwain H; Levy R; Wolfe F; Weisman M; Zeng Q; Morrison B; Bolognese J; Seidenberg B; Gertz BJ
    J Rheumatol; 1999 Nov; 26(11):2438-47. PubMed ID: 10555907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee.
    Kivitz A; Ma C; Ahdieh H; Galer BS
    Clin Ther; 2006 Mar; 28(3):352-64. PubMed ID: 16750450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035 Study Group.
    Cannon GW; Caldwell JR; Holt P; McLean B; Seidenberg B; Bolognese J; Ehrich E; Mukhopadhyay S; Daniels B
    Arthritis Rheum; 2000 May; 43(5):978-87. PubMed ID: 10817549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis.
    Ehrich EW; Davies GM; Watson DJ; Bolognese JA; Seidenberg BC; Bellamy N
    J Rheumatol; 2000 Nov; 27(11):2635-41. PubMed ID: 11093446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rofecoxib shows consistent efficacy in osteoarthritis clinical trials, regardless of specific patient demographic and disease factors.
    Detora LM; Krupa D; Bolognese J; Sperling RS; Ehrich EW
    J Rheumatol; 2001 Nov; 28(11):2494-503. PubMed ID: 11708424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of rofecoxib in patients with chronic low back pain: results from two 4-week, randomized, placebo-controlled, parallel-group, double-blind trials.
    Katz N; Ju WD; Krupa DA; Sperling RS; Bozalis Rodgers D; Gertz BJ; Gimbel J; Coleman S; Fisher C; Nabizadeh S; Borenstein D;
    Spine (Phila Pa 1976); 2003 May; 28(9):851-8; discussion 859. PubMed ID: 12941996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter, randomized, double-blind, active-controlled, parallel-group trial of the long-term (6-12 months) safety of acetaminophen in adult patients with osteoarthritis.
    Temple AR; Benson GD; Zinsenheim JR; Schweinle JE
    Clin Ther; 2006 Feb; 28(2):222-35. PubMed ID: 16678643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studies.
    Birbara C; Ruoff G; Sheldon E; Valenzuela C; Rodgers A; Petruschke RA; Chang DJ; Tershakovec AM
    Curr Med Res Opin; 2006 Jan; 22(1):199-210. PubMed ID: 16393445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and Ibuprofen in the treatment of osteoarthritis of the knee.
    Schiff M; Minic M
    J Rheumatol; 2004 Jul; 31(7):1373-83. PubMed ID: 15229960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of topical diclofenac diethylamine gel in osteoarthritis of the knee.
    Niethard FU; Gold MS; Solomon GS; Liu JM; Unkauf M; Albrecht HH; Elkik F
    J Rheumatol; 2005 Dec; 32(12):2384-92. PubMed ID: 16331769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis.
    Kivitz A; Eisen G; Zhao WW; Bevirt T; Recker DP
    J Fam Pract; 2002 Jun; 51(6):530-7. PubMed ID: 12100776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of rofecoxib therapy on measures of health-related quality of life in patients with osteoarthritis.
    Ehrich EW; Bolognese JA; Watson DJ; Kong SX
    Am J Manag Care; 2001 Jun; 7(6):609-16. PubMed ID: 11439734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.